angststoornissen depression and anxiety major depressive disorder and anxiety disorder
Conditions
Interventions
Antidepressant treatment: Subjects will receive standardized treatment with
selective serotonin reuptake inhibitor (SSRI) which has documented efficacy, a
rather favorable side effect profile, and i
Sponsors
GGZ inGeest (Amsterdam)
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Clients (aged 18-65) can take part if they meet the DSM-IV criteria for a current major depressive disorder (MDD) and/ or current anxiety disorder. Healthy persons can take part if they are aged 18-65 years.
Exclusion criteria
Exclusion criteria: Patient-sample: Current use of antidepressants (antidepressants have to be eliminated for at least 4 weeks for participation of this study), current use of psychotropic medication, except for the use of benzodiazepine for which dosage has to be constant, ongoing participation in regular (>1/week) exercise, primary severe, clinically diagnosed psychiatric diagnosis other than depression or anxiety (bipolar disorder, psychosis, addictive disorder), evidence of acute suicidal risk, medical contra-indications to exercise or antidepressants as confirmed by a physician ;Control-group: lifetime psychiatric disorder, lifetime treatment for psychological symptoms, ongoing participation in regular (>1/week) exercise, medical contra-indications to exercise or antidepressants as confirmed by a physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Is SSRI treatment or exercise therapy in depression and/or anxiety comparable for depression and anxiety symptomatology and physiological stress? | — |
Secondary
| Measure | Time frame |
|---|---|
| Secundary outcome: reduced cellulair aging and metabolic stress after depression and anxiety treatment and change in brain activity after treatment. | — |
Countries
Netherlands
Outcome results
None listed